Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study’ and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid”